FilingSEC EDGAR8-K
Amgen Terminates Research Collaboration and License Agreement with TScan Therapeutics
· SEC accepted
StageTermination
Filing content
Amgen notified TScan Therapeutics of its decision to terminate their 2023 research collaboration and license agreement for Crohn's disease, effective November 10, 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…